INTANGIBLE ASSETS AND GOODWILL (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Minimum age of children for management of nephropathic cystinosis	6 years
Intangible asset impairment recognized	$ 0	$ 0
Amortization charged to research and development expense	60,000	60,000
Summary of intangible assets [Abstract]
Useful Life	20 years
Actual and estimated amortization expense for intangible assets [Abstract]
2015 (remaining 9 months)	178,000
2016	238,000
2017	238,000
2018	238,000
2019	238,000
Research and Development Expense [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization charged to research and development expense	60,000	60,000
Encode Pharmaceuticals, Inc. [Member]
Summary of intangible assets [Abstract]
Total intangible assets	4,110,000				4,110,000
Less accumulated amortization	(1,196,000)				(1,136,000)
Intangible assets, Net	2,914,000				2,974,000
IP license for RP103 [Member] | Encode Pharmaceuticals, Inc. [Member]
Summary of intangible assets [Abstract]
Useful Life	20 years
Total intangible assets	2,620,000				2,620,000
UCSD license FDA and EC approval milestones [Member] | Encode Pharmaceuticals, Inc. [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Milestone payment based on drug approvals			500,000	800,000
Summary of intangible assets [Abstract]
Useful Life	20 years
Total intangible assets	1,250,000				1,250,000
Other Intangible Assets [Member] | Encode Pharmaceuticals, Inc. [Member]
Summary of intangible assets [Abstract]
Useful Life	16 years
Total intangible assets	$ 240,000				$ 240,000